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Abstract Blockade of cytokines, particularly of tumour necrosis factor alpha (TNF-α), in
immuno-inflammatory diseases, has led to the greatest advances in medicine of recent years.
We did a thorough review of the literature with a focus on inflammation models in rodents on
modified gene expression or bioactivity for IL-1, IL-6, and TNF-α, and we summarized the
results of randomized controlled clinical trials in human disease. What we have learned
herewith is that important information can be achieved by the use of animal models in
complex, immune-mediated diseases. However, a clear ranking for putative therapeutic
targets appears difficult to obtain from an experimental approach alone. This is primarily due
to the fact that none of the disease models has proven to cover more than one crucial
pathogenetic aspect of the complex cascade of events leading to characteristic clinical disease
signs and symptoms. This supports the notion that the addressed human immune-mediated
diseases are polygenic and the summation of genetic, perhaps epigenetic, and environmental
factors. Nevertheless, it has become apparent, so far, that TNF-α is of crucial importance in
the development of antigen-dependent and antigen-independent models of inflammation, and
that these results correlate well with clinical success. With some delay, clinical trials in
conditions having some relationship with rheumatoid arthritis (RA) indicate new
opportunities for blocking IL-1 or IL-6 therapeutically. It appears, therefore, that a
translational approach with critical, mutual reflection of simultaneously performed
experiments and clinical trials is important for rapid identification of new targets and
development of novel treatment options in complex, immune-mediated, inflammatory
diseases.
B. Möller ()) . P. M. Villiger
Inselspital Bern, Klinik für Rheumatologie und Klinische Immunologie/Allergologie,
CH-3010 Bern, Switzerland
e-mail: burkhard.moeller@insel.ch . Tel.: +41-31-6328017 . Fax: +41-31-6329745
Springer Semin Immun (2006) 27:391–408
Introduction
Interleukins (IL)-1 and -6, each with more than 30,000 citations, and tumour necrosis factor
(TNF-α) with more than 60,000 citations in the National Library of Medicine (http://www.
ncbi.nlm.nih.gov), have been a research focus for approximately two decades. TNF-α
blockade has made its way to clinical application in several immune-mediated inflammatory
diseases, among them rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis with
or without arthritis (PsA), as well as Crohn’s disease (CD). Despite comparable success for
IL-1 and TNF-α blockade in animal models of inflammation, and despite intensive efforts in
pre-clinical and clinical research, IL-1 and IL-6 have not yet made their way to broad clinical
application. However, new indications appear on the horizon, among them systemic-onset
arthritis in children, adult-onset Still’s disease, and cryopyrin-associated familial periodic
fever syndromes. For these inflammatory disorders, very recent publications indicate a better
effect of IL-1 or IL-6 blockade, compared to blockade of the TNF pathway.
The pathogenesis of most diseases for which anti-cytokine treatment is currently licensed
is still far from being completely understood. However, the evaluation of cytokines as
potential therapeutic targets has allowed insights into some relevant aspects of pathogenesis,
and anti-cytokine treatment, thereby, opened the arena for more rational treatment of different
chronic inflammatory diseases. Conventional pharmacological treatment options are not
necessarily inferior to the clinical effect achievable with one of these new compounds, but the
improved understanding and clearly formulated, experimental evidence-based paradigms for
a central pathogenetic role of the cytokines obviously supported the enormous economic
success of anti-cytokine treatment. Importantly, biological therapies appear to be potent not
only with regard to improvement of clinical manifestations of diseases, but also with regard
to changing the evolution of diseases. They have the potential to prevent disease damage, an
effect that has rarely been achieved to the same extent with any of the conventional drugs.
The urgent need for new treatment options in hitherto untreatable conditions has opened
the arena for cytokine blockade, so far, with convincing data for efficacy and well-
documented safety. This success was obviously expected, but not clearly predictable with
regard to pleiotropic mediators and complex redundancies of the cytokine network. This
review will summarize the currently available data on anti-IL-1, anti-IL-6, and anti-TNF-α
treatment from a clinical perspective, with a brief overview of the molecular aspects, some
key data from knock-out and transgenic animals, and the growing knowledge of results in
randomized controlled trials.
Cytokines and corresponding receptors
IL-1 is a pleiotropic cytokine, that was first described in 1979 as a pyrogen and leucocyte
activating factor (LAF) with activating properties on T and B lymphocytes, monocytes and
macrophages, osteoblasts, fibroblasts, muscle cells, and endothelial and epithelial cells.
Clinical symptoms are related to responses in the liver (acute-phase reaction), central nervous
system (fever) and in the kidney (natriuresis). Further work was facilitated when IL-1β was
cloned in 1984. Despite a low (27%) homology of the primary protein structures, the similar
three-dimensional structures of the essential domains explain an almost identical function of
IL-1α and IL-1β. The major sources of IL-1 are the activated cells of the monocyte-
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phagocytic system, and its production can be rapidly induced by bacterial lipopolysaccha-
rides (LPS), TNF-α, interferons α, β and γ, and IL-1 itself. The molecular mass of both
forms is approximately 17 kDa, and both forms are synthesized as pro-peptides of 35 kDa. A
number of proteases are capable of cleaving the pro-peptides to their mature forms. There
exist several regulatory and structural differences of potential clinical importance between
the two IL-1 molecules: human IL-1α and IL-1β are encoded by different genes on
chromosome 2 (IL-1α 2q13, IL-1β 2q13-21), and the promoter of the IL-1β gene is 50-fold
stronger in its regulation than the promoter of the IL-1α gene. Only the inactive pro-IL-1β
becomes activated and secreted upon activation of the P2X7 ATP receptor by the specific
protease IL-1 converting enzyme (ICE). In contrast, membrane-bound IL-1 activity is
exclusively represented by IL-1α. Despite these differences in expression and maturation of
the ligands, both IL-1 forms show identical binding capacity to the two known IL-1
receptors. The 80-kDa type I receptor (IL-1RI) mediates cell activation with involvement of
the IL-1R accessory protein (IL-1RAcP) by subsequent phosphorylation of the IL-1 receptor-
associated kinase IRAK. In constrast, the 60-kDa type 2 receptor (IL-1RII) lacks cell
activating properties and acts exclusively as a decoy receptor. IL-1 receptor antagonist (IL-
1ra), a glycosylated 23- to 25-kDa soluble protein, is able to block the action of both IL-1
forms by binding to the type I receptor with a complete lack of receptor activation. It provides
an outstanding safety and tolerability profile even when administered in high doses (data
summarized from [1–3, and 8]). Therefore, this molecule was chosen for therapeutic
application.
Like the IL-1 molecules, IL-6 is also a pleiotropic cytokine predominantly expressed in
activated monocytes or macrophages, but also in fibroblasts or activated endothelial cells of
inflamed tissues. Similar to IL-1, IL-6 is inducible by LPS, TNF-α, and some interferons.
The gene corresponding to human IL-6 is located on chromosome 7q21-p14. IL-6 is present
in at least five different forms of glycosylated 21.5- to 28-kDa proteins. Its variability is
predominantly related to posttranslational modification. IL-6 acts on its specific receptors,
one with a high (kd 10–11 M), and one with a 2-log-lower binding affinity, probably by
posttranslational modification of the same receptor. Hetero-dimerization of the IL-6R with
the gp130 transmembrane glycoprotein leads to subsequent downstream activation of T cells,
monocytes, and mitogen-activated B cells either via STAT-3 signaling or via activation of the
MAP kinase pathway.
The question whether IL-6 is a pro- or an anti-inflammatory cytokine was discussed on
many occasions. It is induced by IL-1 and TNF and immediately follows their expression.
However, regarding the biological effects, IL-6 not only induces signs of acute inflammation,
such as fever and raises of CRP, but also elicits anti-inflammatory effects. These include the
synthesis of ACTH, thereby activating a negative feedback loop of inflammation and a link
to the neuroendocrine system, or the expression of tissue inhibitor of metalloproteinases
(TIMP) by synoviocytes and chondrocytes. Furthermore, IL-6 induces the terminal
differentiation of B cells to plasma cells, which led to the descriptive name B-cell
differentiation factor (BCDF). IL-6 represents an important survival factor for myeloma cells
(data summarized from [4, 5, 8]).
Tumour necrosis factors alpha (cachectin) and beta (synonym of lymphotoxin-alpha) were
initially detected in the peritoneal fluid of mice vaccinated with viable Bacillus Calmette-
Guerin. The supernatant showed cytostatic effects or cytotoxicity in various malignancies,
but not in non-malignant cells. TNF-α is a non-glycosylated 17-kDa protein, predominantly
produced in macrophages, CD4+, but also CD8+ T cells, activated NK cells and neutrophils.
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The TNF-α gene is closely located in the HLA molecules on chromosome 6 (6q23-6q12).
The protein production is inducible by interferons, IL-2, and IL-18. TNF-α is transported
to the cell surface and presented on the cell membrane. It can interact with TNF receptors of
neighbouring cells or be cleaved and released from the cell surface by the TNF-alpha
converting enzyme (TACE). Release from the cell surface appears of less importance for the
biological function of the TNF-α molecule. Either the cell-bound or soluble ligand binds to
TNF receptors I (p55) and II (p75) that are responsible for the divergent actions of TNF-α.
Binding to p55 is linked to activation of the caspase pathway, resulting in programmed cell
death, while cell activation through activation of the nuclear factor kappaB system is mostly
mediated by the p75 receptor. Trimerization of the TNF receptor is required for ligand
binding sufficient for signaling and activation of the downstream pathways. Soluble TNF
receptor molecules can bind TNF-α locally at sites of inflammation as well as systemically.
The ligand and receptor stoichiometry is of major importance for this interaction and has
been incorporated in the design of soluble TNF receptors for clinical application (data
summarized from [6–8]).
Table 1 Overview of models for immune-mediated diseases using transgenic or knock-out animals for IL-1,
IL-6 and TNF-α
Genetics/phenotype Antigen-
induced
Mediator-induced Spontaneous
Inhibited IL-1 bioactivity
IL-1α knock out CIA ↓ [12] HTLV-1-Tg ↓ [12]
IL-1β knock out CIA ↓ [12] HTLV-1-Tg ↓ [12]
IL-1α/β knock out CIA ↓↓ [12] HTLV-1-Tg ↓↓ [12]
IL-1RI knock out SIA ↓↓ [15]
IL-1ra transgenic CIA ↓↓ [13, 14]
Augmented IL-1 bioactivity
IL-1α transgenic Arthritis [9]
IL-1ra knock out Arthritis [11]
Recombinant IL-1β AIA ↑ [15]
Inhibited IL-6 bioactivity
IL-6 knock out CIA, AIA ↓(↓)
[24, 25]
SIA unaffected [15]
Augmented IL-6 bioactivity
IL-6 transgenic Nephritis [20]
gp130 mutation Arthritis [22]
Inhibited TNF-α bioactivity
TNF-α knockout SIA (↓) [15]
TNF-RI knockout CIA ↓ [37] SIA unaffected [15]
TNF-RII knockout SIA unaffected [15]
TNF-RI/RII knockout SIA unaffected [15]
AIA ↓↓ [16]
Augmented TNF-α bioactivity
transgenic for human or murine
TNF-α
Polyarthritis, spondylitis,
colitis (reviewed in [32])
Recombinant TNF-α AIA ↑ [15]
AIA Antigen-induced arthritis, CIA collagen-induced arthritis, SIA serum-induced arthritis
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Genetic modification of IL-1, IL-6, and TNF-α in animal models of immune-mediated
inflammation
A large body of evidence demonstrating the importance of IL-1, IL-6, and TNF-α has been
accumulated in the meantime in several overexpression or knock-out animal models
(Table 1). Most of the published data concern the development of arthritis, while the literature
on genetically defined animal models for other target organs, such as colitis, skin
inflammation, nephritis or CNS inflammation, and other important human inflammatory
diseases, is clearly less extensive.
Cytokine effects on arthritis symptoms in mice show substantial variation and must be
carefully interpreted, taking into account the specific background of different, always
artificial, disease models. Spontaneous arthritis with 100% disease penetration occurs in IL-1
and TNF transgenic animals, and in some conditions also in animals with boosted IL-6
activity, thus providing evidence for arthritis induction by elevated cytokine expression itself,
which mainly appears to be independent of defined co-conditions or environmental
conditions.
Antigen-dependent arthritis models, such as collagen-induced arthritis (CIA), in which
mice do not develop arthritis spontaneously, but only upon immunization with type II
collagen (CII) in the presence of Freund’s adjuvant, are widely used for studies on the role of
prophylactic or therapeutic administration of recombinant anti-cytokine proteins. This model
includes all phases of immune reaction and inflammatory response.
The model of serum-transfer-induced arthritis is independent of antigen processing,
presentation, and immunoreaction, but predominantly addresses the downstream processes
of inflammation. Arthritis in this model is driven by injection of K/BxN serum from K/BxN
T-cell receptor transgenic mice into naïve animals. Usually, C57Bl/6 mice are used here,
which can be genetically modified for the interesting cytokine gene. Antibodies from the K/
BxN serum bind to different cartilage epitopes of C57Bl/6 mice and propagate arthritis. As an
alternative, arthritis independent of antigen recognition and subsequent immunization can
also be triggered by direct injection of CII antibodies.
Consequences of IL-1 modification in animal models
Human IL-1α transgenic C57BL/6N × B6C3F1 mice develop a spontaneous, macrophage-
and neutrophil-dominated type of arthritis. The neutrophilia is apparently mediated by
induced GM-CSF [9]. IL-1α transgenic mice with a mutation of Lys64 to Ala271 of the
human IL-1α amino acid sequence exhibit overproduction of membrane-associated IL-1 on
macrophage and fibroblast surfaces. This results in a more severe phenotype than mice only
transgenic for human IL-1α on the same genetic background, indicating that not only the
quantity of IL-1α but also the sterical order or the association with other membrane
components might be of functional relevance for IL-1 ligand/receptor interaction and disease
development [10]. The importance of IL-1ra to control IL-1 activity was indicated in the
spontaneous arthritis model of IL-1ra-deficient BAL/cA mice (which was not reproducible in
C57BL/6J mice), so far suggesting influence of the IL-1/IL-1ra balance on arthritis
development in certain conditions [11].
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The pathogenic relevance of both IL-1α and IL-1β was further underlined when
comparing induction of CIA in IL-1α−/−, IL-1β−/−, or IL-1α/β−/− animals with wild-type
littermates on a DBA/1J background [12]. CII antibody production in CIAwas still normal,
but deficiency of IL-1α and IL-1β, and more so of both IL-1 molecules, ameliorated arthritis.
In line with this, mice transgenic for IL-1ra were protected from CIA [13, 14]. In the HTLV-I
Tg model, in which BALB/c IL-1β−/−, IL-1α/β−/− mice crossed with HTLV-I transgenic
mice showed a T-cell proliferative syndrome with arthritis, T-cell response and autoantibody
production was clearly suppressed by IL-1α and IL-1β deficiency [12]. Comparing the
results in CIA and HTLV-1-Tg led the authors to conclude that murine IL-1 is of importance
for the T-cell-dependent processes of autoimmunity and arthritis [12].
Data from the serum-transfer model—which progresses independently of antibody
formation—also supported a central role for IL-1-mediated processes in murine arthritis. In
this study, mice were knocked out for IL-1R (type 1 equivalent), and also for IL-6, TNF-α
and lymphotoxin, the p55 TNF-R1 and p75 TNF-R2 [15]. Interestingly, the most robust
prevention of arthritis was observed in IL-1R knock-out animals, whereas, IL-6 and LT
deficiency had no effect on the onset and course of serum-induced arthritis. TNF-α ligand
knock-out mice had a variable and TNF-R knock-out mice a surprisingly unaffected disease
course [15]. The equal importance of IL-1 and TNF-α in the induction and severity of
arthritis was suggested by the addition of TNF-α and IL-1β to CII antibodies with similar
enhancement of antibody induced arthritis [15].
Other studies confirmed a pivotal role for IL-1 and TNF-α in models that are independent
of antibody formation [16]. The inhibitory effect of IL-1R deficiency on the development of
serum-transfer-induced arthritis could be circumvented by activating the downstream IL-1
pathway, e.g., by activating the myeloid differentiation factor MyD88 by LPS and TLR-4
signaling [17]. This suggests that other factors, such as products of gram-negative microbes
binding to Toll-like receptors (TLR), may substitute for inhibited IL-1 effects.
To our knowledge, none of the IL-1 transgenic mice, or the IL-6 or TNF-α transgenic
mouse models described so far evolved a spontaneous skin disease resembling that of
psoriasis in human. Beta-1 integrin transgenic mice, however, over-express this molecule
exclusively at the basal skin layer. They experience a sporadic psoriasis-like phenotype and
display secondary up-regulation of IL-1αmolecules in suprabasal skin layers upon activation
of MAP kinases [18]. Inducible epidermal deletion of nuclear proteins c-Jun and Jun B also
leads to a psoriasis-like phenotype of the skin and also the joints [19]. Notably, and in
contrast to the skin phenotype, the development of arthritic lesions required T and B cells and
signaling through tumour necrosis factor receptor 1 (TNFR1) in this model.
Modulation of IL-6 activity in animal models
The contribution of IL-6 to the development of arthritis, when examined in IL-6 deficient or
transgenic mice, appears more controversial than that of IL-1. IL-6 transgenic mice develop
massive polyclonal plasmocytosis, which is in line with the role of IL-6 as a factor of B-cell
differentiation [20]. IL-6 is known as an important growth factor for plasmocytoma cells. No
malignant B-cell transformation occurs in this model, but in the presence of additional check
point defects (such as mutation in the c-myc gene [21]) malignant transformation can be
observed. No spontaneous arthritis occurred in the IL-6 transgenic mice mentioned so far,
396 Springer Semin Immun (2006) 27:391–408
although several autoimmune phenomena, such as autoantibody formation or autoimmune-
mediated nephritis, were reported [20]. When the gp130 molecule is point-mutated to Y759F,
leading to prolonged STAT-3 activation upon activation of the IL-6 receptor complex, late
developing, spontaneous arthritis in C57BL/6 mice was induced [22].
An important clinical aspect of autoimmune diseases in juvenile individuals is a reduced
longitudinal growth in chronic inflammation. As a correlate of this problem, NSE-h-IL-6
transgenic mice show significantly reduced weight gain and growth, which is explained by
reduced insulin-like growth factor activity (IGF)-1 [23]. In this case, a special indication for
IL-6 blockade in the treatment of children with inflammatory conditions may arise. The
currently available mouse data suggest a relevant contribution of IL-6 in antigen-induced
arthritis [24, 25], but IL-6 is not required for arthritis development in TNF transgenic mice
[24].
The role of IL-6 was also investigated in experimental autoimmune encephalomyelitis
(EAE) induced by immunization with myelin oligodendrocyte glycoprotein (MOG), an
animal model for a demyelinating disease, multiple sclerosis. In this case, the resistance to
EAE in IL-6-deficient mice was associated with a deficiency of MOG-specific T cells [26].
Antagonising IL-6 levels by a monoclonal IL-6 antibody in the trinitrobenzenesulphonic
(TNBS) acid-induced colitis model in Wistar rats to some extent normalized the impaired
linear growth of these animals, although this was not completely explained by normalized
food intake, but by anti-IL-6 treatment-associated normalization of insulin-like growth factor
activity [27]. This observation further supports a direct role of IL-6 in growth regulation. In
the dextrane sulphate-sodium-induced colitis model, IL-6−/− animals showed a reduced
STAT-3 activation, indicating that the SH2 protein induced by IL-6 and STAT-3 tyrosine
phosphorylation plays an essential role in the negative regulation of cytokine signaling [28].
Phenotype of animals transgenic or blocked for TNF-α
Different TNF-transgenic mouse strains have been developed on the C57BL/6CBA
background with the CIA-resistant MHC haplotypes H-2k and H-2b. Stable human TNF-α
overexpression has been achieved by cloning the human TNF-α gene with the 3′-modified β-
globin UTR instead of the AU-rich element (ARE)-containing 3′UTR [29]. This untranslated
gene region is crucial for the degradation of TNF transcripts that prevents TNF-α protein
expression in resting cells. In activated cells, stability and translational efficiency of TNF-α
mRNA is increased by mechanisms mediated by this gene sequence. Other models express a
murine TNF-α transmembrane mutant either with the 3′-modified β-globin UTR [30] or an
ARE-deleted mouse TNF-α gene, called TNFΔARE [31]. Human TNF-α can exclusively
bind to the murine TNF-RI, while the murine isoform binds to both receptors. Different
phenotypes of TNF-transgenic rodents have been developed. Overexpression of human
TNF-α was predominantly associated with spontaneous polyarthritis, while murine TNF-α
transgenic mice developed spondylitis, inflammatory bowel disease, or polyarthritis
dependent on the particular genetic model [32]. The different modifications of human and
murine TNF-α genes do not completely resolve some controversies about the functional
consequences of activating the TNF-RI or TNF-RII, or a differential effect of the soluble or
membrane-bound protein form [32].
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Administration of anti-TNF-α antibodies was able to prevent arthritis in TNF-Tg mice
[29]. The same was also true for antibody blockade of the IL-1RI, indicating that IL-1 is a
potent downstream mediator of TNF-α in the pathogenesis of arthritis in these mice [33].
TNF-α serum concentrations were reduced in the IL-1R antagonist-treated TNF-α Tg mice.
This underlines the well-known interrelationship regarding expression and function of IL-1
and TNF-α. TNF-Tg mice crossed with RAG-1 knock-out mice, which have no T cells or B
cells, also develop erosive arthritis [34]. This circumstance indicates an immune-independent
disease development. However, backcrossing of TNF-Tg onto an arthritis susceptible DBA/1
(H-2q) background promotes earlier arthritis development and suggests a link between raised
levels of circulating TNF-α and immune-mediated processes [35]. Antigen-mediated B-cell
dependent immune responses were not impaired in TNF-deficient, BAFF transgenic mice,
although knocking out TNF led to a significant increase of B-cell lymphomas in the context
of growth-factor-mediated B-cell stimulation [36].
Deletion of both TNF-R prevented disease in CII-antibody-induced arthritis of BALB/c
mice [16], but had no effect on the development of arthritis in K/BxN mice. The latter,
somewhat unexpected observation may be explained by the presence of other receptors of the
TNF family, or up-regulation of downstream mediators in receptor-deficient mice that
compensate for the TNF-R1/2 deficiency [15]. Also, TNF-α deficiency led to random
development or protection from serum-induced arthritis, which appeared to depend on
environmental rather than epigenetic factors [15]. This observation reflects the situation in
CIA, where p55 TNF-R1 deficiency reduced the incidence and severity of arthritis
development [37].
Breakdown of self-tolerance by presentation of a foreign antigen in a specific arthritis-
susceptible MHC background is a widely accepted hypothesis for the development of chronic
inflammatory processes in humans. This led researchers to follow the generation of the T-cell
receptor repertoire and antigen response in mice transgenic for susceptible and non-
susceptible human MHC II molecules. It is noteworthy that stimulation of these animals with
a potential antigen, human cartilage protein gp-39, led to a differential T-cell cytokine profile,
with more TNF-α production in susceptible than in non-susceptible animals [38].
Importantly, however, chronic exposure of T cells to TNF-α impaired T-cell receptor
signaling. Among other contributing factors, this observation may explain the frequently
reported anergy of T cells in chronically inflamed tissues such as RA synovial membranes
[39].
Summarizing the extensive literature on IL-1, IL-6, and TNF-α in various models in
rodents, it appears appropriate to rank IL-1 equivalent or even superior to TNF-α, while IL-6
presents as a less attractive target molecule in immune-mediated inflammation.
Blockade of IL-1, IL-6, and TNF-α in human disease
As already mentioned in the introductory section, TNF-α blockade has made its way into
clinical application, whereas, IL-1 and IL-6 blockade have not yet finished this process. What
may be the reason for this?
All three molecules, IL-1α, IL-1β, and TNF-α are not the exclusive representatives of the
IL-1 or TNF protein families. However, with respect to significant up-regulation in human
disease and the enormous potential when modifying expression of one of these cytokines or
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the respective receptors in rodent models of disease, it appears justified to suggest highest
importance for IL-1, IL-6, and TNF-α. Some divergent results for the candidate cytokines in
the rodent models were dependent on the genetic or environmental background. Differences
were sometimes subtle, and the results were not always absolutely concordant.
Switching from experimental medicine to the perspective of a clinician, compounds for
antagonizing IL-1, IL-6, and TNF activity and a large body of evidence in clinical application
have become available. In the following section, we will focus on the effect of these drugs in
prospective, randomized controlled trials (RCT).
IL-1 inhibition in human diseases
IL-1 antagonism in published RCT was accomplished by injecting or infusing recombinant
IL-1ra in patients with sepsis [40–42], rheumatoid arthritis [43–45], and in graft vs host
disease in patients undergoing allogeneic stem-cell transplantation [46]. Preliminary data
also exist for stroke [47], osteoarthritis [48], and spondylitis [49, 50]. Despite excellent data
from animal models, and although activation of the IL-1 system has been described in several
human conditions, clinical data have either proven ineffective or at least been controversial in
terms of achievable results. The best evidence for effectiveness of blocking IL-1 currently
exists for the erosive aspect of arthritic joints, while satisfactory clinical response to IL-1ra
was rather infrequent even in RA trials. Also, addition of IL-1Ra to TNF blockade did not
lead to increasing efficacy, but to accumulation of side effects [51]. Published clinical data on
the effect of IL-1ra on colitis, psoriasis, nephritis, or encephalomyelitis are still missing. A
few, but very convincing, case reports suggest a novel indication for IL-1ra in rare inherited
auto-inflammatory disorders [52].
IL-6 blockade in human conditions
Randomized controlled trials for IL-6 inhibition have been published in the meantime for RA
[53, 54]. First trials were also done in Crohn’s disease [55] and in juvenile idiopathic arthritis
(JIA) [56, 57], in the latter indication with a special focus on the systemic onset subtype of
JIA. This subtype is of particular interest, firstly because this entity is reported to be linked to
a single nucleotide mutation in the IL-6 gene [58], and secondly because of the unfavourable
outcome of systemic onset JIA upon TNF blockade. All the cited studies on IL-6 antagonism
were performed with an IL-6R blocking, humanized antibody called tocilizumab (MRA). In
line with the important pathogenetic role of IL-6 in this disease [59], MRA has also been
successfully tested when shorter dose intervals than indicated in Table 2 were used in
Castleman’s disease, a lymphoproliferative syndrome of non-malignant origin [60]. Affected
patients suffer from lymphadenopathy, fever, general malaise, and wasting. Thus, increased
plasma lipid concentrations were intended in these patients, but raised total and HDL
cholesterol as well as triglycerides have also been reported in the RA trials. These parameters
have to be kept under critical observation in ongoing studies for RA, a disease with an
elevated risk per se for cardiovascular complications. As also suggested by the metabolic
effects observed in the animal models, IL-6 blockade in patients also led to a significant
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decrease of collagen cross-link products, as well as an increase of bone-formation-indicating
parameters [54].
TNF blockade in human diseases
TNF-α blockade has proven efficacy in randomized controlled trials for several immune-
mediated human diseases. Three TNF-binding recombinant protein constructs have entered
the market since their first approval in 1998 in the US and EU: (1) Infliximab (cA2), a
chimeric anti-TNF-α IgG1 antibody; (2) etanercept, a human dimeric TNF-receptor type II-
IgG1 fusion protein (TNFR:Fc); and (3) adalimumab (D2E7), a human anti-TNF-α IgG1
antibody genetically engineered through phage display technology. At present, a fourth
TNF-α binding protein, certolizumab (CDP870), a polyethylene-glycolated Fab’ fragment of
anti-tumor necrosis factor is still in the pre-approval phase. Table 2 summarizes some key
clinical trials and basic information on the available drugs.
Efficacy of TNF blockers in RA
Head-to-head comparison of the anti-TNF constructs in RA is missing, but with all the
necessary caution to be taken, the null hypothesis of equivalence in terms of efficacy and
safety when targeting TNF-α by different biologics has not been rejected, so far, for this
indication. Significant improvement in signs and symptoms of RA (ACR20 response) was
two to three times more likely than in placebo-treated control patient cohorts when adding
infliximab or etanercept to methotrexate in active disease [61, 62]. Efficacy of TNF-αwas up
to five times higher than placebo when added to standard methotrexate and concomitant
treatment in a later trial [63]. When recruiting severe cases of RA for these first trials on TNF
Table 2 Cytokine blocking recombinant proteins in clinical trials
Substance Target Administration/maintenance Clinical indication
Adalimumab (D2E7) TNF-α s.c., 40 mg every other week RA [63], PsA [70]
Anakinra
(IL-1Ra)
IL-1 s.c., 100 mg once daily RA [44]
Certolizumab
(CDP870)
TNF-α i.v. or s.c., starting dose
up to 400 mg
RA [99], Crohn [100]
Etanercept
(TNFR:Fc)
TNF-α s.c., 25 mg twice weekly RA [62], JIA [71], AS [66],
psoriasis and PsA [67]
Infliximab (cA2) TNF-α i.v., 3 (5–10) mg/kg every
(4–)8 weeks
RA [61], AS [64, 65], psoriasis [69],
and PsA [68], Crohn [84, 85]
Tocilizumab
(MRA)
IL-6 i.v., 4–8 mg/kg every
4 weeks
RA [53, 54], JIA [55, 56]
AS Ankylosing spondylitis, i.v. intravenous infusion, JIA juvenile idiopathic arthritis, PsA psoriatic arthritis,
RA rheumatoid arthritis, s.c. subcutaneous injection, SLE systemic lupus erythematosus
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blockade, the new compound was added to standard medication including methotrexate. The
response to different TNF blocking agents may differ in individual RA patients, and
sequential attempts using more than one compound due to primary failure or secondary loss
of efficacy of the first agent is justifiable. The reason for occasional individual differences in
the response to TNF antagonists is difficult to identify: the induction of antibodies against the
applied proteins was assumed to cause a loss of efficacy, but accumulated data from several
clinical trials do not support a major contribution of antibody induction for this observation.
Efficacy of TNF blockers in other arthritides
Concomitant treatment with immunosuppressants was primarily considered to reduce
antibody induction against the chimeric antibody infliximab, until application in AS proved
efficacy in the absence of immunosuppressive co-medication [64]. Two studies with
etanercept in AS patients were similarly performed without immunosuppressive co-
medication, one with a two-to-three times higher probability of reaching the primary
outcome endpoint than placebo [65], and the other with an even nine- to tenfold superiority
over placebo [66]. All launched TNF-blocking agents have proven efficacy in psoriasis and
psoriatic arthritis for both articular and skin manifestations independent of concomitant
methotrexate treatment [67–70]. The likelihood of a disease flare was also reduced by one- to
two-thirds of that observed in placebo-treated children with juvenile idiopathic arthritis [71],
although the response in systemic onset JIA, as well as uveitis manifestation, appeared less
favourable [72, 73].
Safety of TNF blockers
It was the observation of infrequent but serious side effects in 2001, when more than 250,000
patients were already exposed to infliximab or etanercept, which transiently slowed the
enthusiasm for TNF blockade. In this review, an increased risk of opportunistic infections
and exacerbation of latent tuberculosis (http://www.rheumatology.org/publications/
hotline/0901tnf.asp, as well as increased mortality when treating patients with advanced
cardiomyopathy within clinical trials became apparent [74, 75]. Physicians have rapidly
learned to ensure safety and protection from these complications by appropriate pre-
treatment screening. At present, an acceptable short-term risk of non-opportunistic
infections and allergic reactions to the compound still appear to be the price to pay for
achieving superior efficacy by adding TNF blockade to conventional treatment [76]. The
risk of lupus-like syndromes, one of the major concerns in previous development of TNF
blocking agents, is now considered less important than previously expected [77, 78].
However, an increased risk of lymphoma due to TNF antagonism cannot yet be completely
ruled out, although its appearance may be delayed (http://www.rheumatology.org/
publications/hotline/0303TNFL.asp).
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TNF blockade in early or established RA?
However, accompanying the optimized efficacy, increased rates of non-opportunistic
infections (pneumonia) were observed when TNF blockade was combined with standard
treatment, including methotrexate, even in patients with early-stage RA [76]. This, together
with the arguable superiority of TNF blockade over standard methotrexate treatment, starting
with a head-to-head comparison in an RCT for early RA [79], and especially equivalence of
the group with later switch to TNF blockade, leads us to the following conclusion. Before
making definitive recommendations, we must wait for more evidence, perhaps from longer
observation of ongoing studies, to better estimate the significance of additive TNF blockade
for the early state of inflammatory conditions [80]. However, in advanced, active RA, the
superiority of the combination of TNF-α blockade and conventional anti-inflammatory
compounds has been more clearly shown [81].
TNF blockade in other immune mediated conditions
Different degrees of efficacy of the various TNF-blocking agents was suggested in the
treatment of some entities. For example, disease activity in Crohn’s disease was ameliorated
by infliximab treatment [82], and the chance of complete healing of the fistulas was three to
five times higher than observed in the placebo control cohort [83], while RCT of other TNF
blocking agents for this condition are still lacking. In this review, it was thus tempting to
speculate that a specific interaction of the effective compound beyond reducing the amount
of soluble TNF-α, e.g., interaction with membrane-bound TNF-α, might be of importance.
Recent work suggests some differential effects on T-cell apoptosis, but the situation is still
somewhat controversial [84–87]. Besides its effectiveness in Crohn’s disease, other types of
mucosa-associated pathology, e.g., active ulcerative colitis, could also be significantly
ameliorated by infliximab treatment [88] as were cutaneous symptoms of Behçet’s disease
when treated with etanercept [89]. Despite some clinical casuistic evidence of successful
treatment of other inflammatory conditions with TNF blocking agents [90], strong proof
from RCTs of the safety and efficacy of TNF blocking agents is lacking. So far, evidence for
a relevant action in systemic lupus erythematosus [78] is limited, and the data are negative for
Sjoegren’s disease [91, 92], or for maintenance therapy in Wegener`s granulomatosis [93].
Future perspectives
The potential of treating human immune-mediated diseases with recombinant proteins is still
open. Looking back at the long but rapid journey from the discovery and validation of targets
to the development of treatment options for IL-1, IL-6, and TNF-α may teach us a lot about
future activities in the field. Critical knowledge has been obtained from animal models, but
there may well be a considerable divergence between the preclinical expectations and the
reality in the treatment of human disease.
Besides the scientific and medical aspects, financial implications have interfered with the
introduction of expensive treatment into the medical systems of various countries. It has
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become increasingly clear that economic evaluation of TNF blockade and of other
recombinant proteins for the treatment of chronic immune-mediated conditions is of major
importance. We need to consider the underlying condition, current disease activity, functional
status, expected progression and treatment duration, and the individual dosing regimen. First
data for RA and AS suggest that a financial cost acceptable to society is achievable [94, 95].
Here, relevant, e.g., genetic, indicators for successful therapy [96] could be of major
importance for avoiding unnecessary costs.
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